Business
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results
First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platformEnrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroend
About this update from Perspective Therapeutics, Inc.
[{"type":"image","alt":"Perspective Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Perspective Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QSFbVndZiJCez3FgWA5yTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9","width":300,"height":63}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First of several clinical updates through mid-2026 accepted for presentation at the 2025 American Society of Clinical Oncology Annual Meeting, with recruitment progressing for all three of our clinical stage potential new medicines based on our next generation targeted radiopharmaceutical technology platform","length":309,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment ongoing for VMT-α-NET, a next generation SSTR2-targeting potential new medicine, with 40 patients enrolled through end of April 2025 in Cohort 2 of the Phase 1/2a trial in neuroendocrine tumors","length":204,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment ongoing for VMT01, a first-in-class MC1R targeting potential new medicine, with first patient treated at a new monotherapy dose level in April 2025, following the first patient treated in combination with the PD-1 inhibitor nivolumab in March 2025","length":258,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved first-in-human dosing of PSV359, which targets FAP-α, associated with multiple highly prevalent solid tumors with patients in need of additional treatment options","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancing our U.S. manufacturing capabilities to enable the delivery of finished product to meet the growing clinical trial and future commercial demands across major U.S. cancer centers","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and short-term investments of approximately $212M as of March 31, 2025 expected to be sufficient to fund current planned clinical milestones and operational investments into late 2026","length":206,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1334,"olType":false},{"type":"text","content":"...